Pfizer Inc. (BKK:PFIZER19)
Thailand
· Delayed Price · Currency is THB 16.50
+0.40 (2.48%)
At close: Dec 4, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Primary Care Revenue | 27.79B | 30.14B |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Care Revenue | 17.21B | 16.65B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue | 16.46B | 15.61B |
Log In |
Log In |
Log In | Upgrade
|
| Global Pharmaceuticals Business (Biopharma) Revenue | 61.47B | 62.40B |
Log In |
Log In |
Log In | Upgrade
|
| Business Innovation (Pfizer CentreOne) Revenue | 1.26B | 1.15B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 61.00M | 81.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 62.79B | 63.63B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue | 37.18B | 38.69B |
Log In |
Log In |
Log In | Upgrade
|
| Developed Markets Revenue | 16.55B | 16.06B |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue (Post-FY2023 Reporting) | 9.06B | 8.88B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 62.79B | 63.63B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue | 37.18B | 38.69B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 62.79B | 63.63B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography 3
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue | 37.18B | 38.69B |
Log In |
Log In |
Log In | Upgrade
|
| Developed Europe Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Developed Rest of World Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| International Revenue | 25.61B | 24.94B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 62.79B | 63.63B |
Log In |
Log In |
Log In | Upgrade
|
EBT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Global Pharmaceuticals Business (Biopharma) Earnings | 28.80B | 28.14B |
Log In |
Log In |
Log In | Upgrade
|
| Other Business Activities Earnings | -8.17B | -7.38B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Comirnaty Direct Sales and Alliance Revenue | 5.48B | 5.35B |
Log In |
Log In |
Log In | Upgrade
|
| Eliquis Alliance Revenue and Direct Sales | 7.77B | 7.37B |
Log In |
Log In |
Log In | Upgrade
|
| Prevnar Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Paxlovid Revenue | 2.87B | 5.72B |
Log In |
Log In |
Log In | Upgrade
|
| Prevnar Family Revenue | 6.34B | 6.41B |
Log In |
Log In |
Log In | Upgrade
|
| Nurtec ODT/Vydura Revenue | 1.41B | 1.26B |
Log In |
Log In |
Log In | Upgrade
|
| Abrysvo Revenue | 751.00M | 755.00M |
Log In |
Log In |
Log In | Upgrade
|
| Vyndaqel Family Revenue | 6.24B | 5.45B |
Log In |
Log In |
Log In | Upgrade
|
| Xeljanz Revenue | 1.11B | 1.17B |
Log In |
Log In |
Log In | Upgrade
|
| Ibrance Revenue | 4.18B | 4.37B |
Log In |
Log In |
Log In | Upgrade
|
| Vaccines Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Internal Medicine Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Hospital Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Inflammation & Immunology Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|